I
Iptacopan
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Post-marketing information
Patient Alert Card
Patient Medication Guide
Physician Educational Material
Subsidy Information and Financing Scheme
No
Active ingredient: Iptacopan
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Eculizumab 300 mg concentrate for solution for infusion as monotherapy for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) in adults and children.
Funding status
[R] Eculizumab 300 mg concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 April 2026.
[R] Eculizumab should be used in line with the additional clinical criteria listed in the Annex.
[NR] MAF assistance does not apply to iptacopan or ravulizumab for treating PNH or aHUS.
Post Marketing Information
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.